NCT02577523 - A Clinical Study of Efficacy, Safety, Tolerability and PK of ND0612H in Subjects With Advanced Parkinson's Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 29, 2015

Primary Completion Date

December 20, 2016

Study Completion Date

January 31, 2017

Conditions

Parkinson's Disease

Interventions

DRUG

ND0612 (Levodopa/Carbidopa solution)

The total daily dose of levodopa/carbidopa 720/90 mg. Device: CRONO TWIN pump system.

DRUG

ND0612 (Levodopa/Carbidopa solution) + morning oral IR-LD/CD

The total daily dose levodopa/carbidopa from ND0612 538/67 mg. Morning dose of oral IR-LD/CD 150/15 mg. Device: CRONO TWIN pump system.

Trial Locations (11)

Fondazione Ospedale San Camillo - I.R.C.C.S., Venice

University of Cincinnati, Cincinnati

QUEST Research Institute, Farmington Hills

AOU Pisa, Pisa

Chaim Sheba Medical Center, Ramat Gan

Northwestern University, Chicago

Sourasky Medical Center, Tel Aviv

University Foundation, Chieti

Rabin Medical Center, Petah Tikva

Medical University Innsbruck, Innsbruck

IRCCS San Raffaele Pisana, Rome